Regulatory News
August 21, 2017 / 12:10 PM / a year ago

BRIEF-Syros receives FDA Orphan drug designation for SY-1425 for treatment of AML

1 Min Read

Aug 21 (Reuters) - Syros Pharmaceuticals Inc

* Syros receives fda orphan drug designation for SY-1425 for treatment of AML

* Syros Pharmaceuticals Inc- ‍look forward to presenting initial clinical data from ongoing Phase 2 clinical trial of SY-1425 in Q4 of this year​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below